DaVita (NYSE:DVA) Trading Down 3.4%

DaVita Inc. (NYSE:DVA)’s stock price traded down 3.4% on Friday . The stock traded as low as $137.63 and last traded at $137.67. 260,304 shares were traded during trading, a decline of 69% from the average session volume of 837,194 shares. The stock had previously closed at $142.50.

Wall Street Analyst Weigh In

DVA has been the subject of several research analyst reports. Truist Financial upped their price objective on shares of DaVita from $135.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, May 15th. TD Cowen raised their price objective on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday. StockNews.com cut shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Finally, Barclays lifted their price objective on DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a report on Monday, May 6th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, DaVita has a consensus rating of “Hold” and an average price target of $146.00.

DaVita Trading Down 3.2 %

The business has a 50-day moving average of $140.68 and a 200 day moving average of $131.01. The stock has a market cap of $12.10 billion, a PE ratio of 15.68, a PEG ratio of 1.10 and a beta of 0.87. The company has a debt-to-equity ratio of 7.95, a quick ratio of 1.37 and a current ratio of 1.43.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.43. The business had revenue of $3.07 billion during the quarter, compared to the consensus estimate of $3.03 billion. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.58 earnings per share. Equities research analysts predict that DaVita Inc. will post 9.62 EPS for the current fiscal year.

Insider Buying and Selling at DaVita

In other news, Director Barbara J. Desoer sold 5,030 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $138.81, for a total transaction of $698,214.30. Following the completion of the transaction, the director now owns 10,954 shares of the company’s stock, valued at approximately $1,520,524.74. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 2.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On DaVita

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raymond James & Associates raised its holdings in DaVita by 135.2% in the fourth quarter. Raymond James & Associates now owns 34,376 shares of the company’s stock valued at $3,601,000 after buying an additional 19,759 shares during the period. Assenagon Asset Management S.A. increased its holdings in DaVita by 2,178.2% in the 4th quarter. Assenagon Asset Management S.A. now owns 108,624 shares of the company’s stock valued at $11,379,000 after purchasing an additional 103,856 shares in the last quarter. Ritholtz Wealth Management raised its position in DaVita by 8.1% in the fourth quarter. Ritholtz Wealth Management now owns 7,675 shares of the company’s stock valued at $804,000 after purchasing an additional 574 shares during the period. Fifth Third Bancorp boosted its position in shares of DaVita by 29.5% in the fourth quarter. Fifth Third Bancorp now owns 4,271 shares of the company’s stock worth $447,000 after buying an additional 973 shares during the period. Finally, Oak Thistle LLC acquired a new stake in shares of DaVita in the fourth quarter valued at about $372,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.